# Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct05283356` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05283356](<https://clinicaltrials.gov/study/NCT05283356>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05283356

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1206 participants.

## Technical summary

Registry record NCT05283356. Randomized; no masking; primary purpose treatment. Start 2022-01-21 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1206 participants (planned count; ClinicalTrials.gov record NCT05283356, source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)
- Started: 2022-01-21 (actual) (ClinicalTrials.gov record NCT05283356, source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT05283356, source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT05283356, source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05283356, source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05283356-2026-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
- Acronym: REAC-TAVI2
- Condition: Severe Aortic Valve Stenosis
- Condition: Aortic Valve Stenosis
- Condition: Transcatheter Aortic Valve Replacement (TAVR)
- Condition: Transcatheter Aortic Valve Implantation (TAVI)
- Intervention (Drug): Ticagrelor 60mg
- Lead sponsor: Fundacin Biomedica Galicia Sur
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)

## Provenance

Content hash: ed61f4a297598d1cf3e1cd101a080e322e192c6803c8e7ebba8f93e4c0321b24
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
